Seedlabs

De Novo NAD+ Exercise-Response Test for Supplement Brands

A test for supplement brands to see how a person's body produces energy molecules after exercise.

A research-use testing service that measures how much a person's quinolinic acid (the direct de novo NAD+ precursor) and KAT4 expression rise after a standardized endurance session, giving NAD+ supplement brands a dynamic, exercise-anchored human endpoint for the tryptophan-to-NAD+ route that static NAD+ blood tests cannot show.

NeuroscienceTryptophan and brain disorders
Metabolism and Genetic DisordersDietary supplement and healthy-aging industry — NAD+ precursor brands substantiating claims with human exercise-challenge data.

Concept

A bundled protocol-plus-assay service (standardized endurance challenge, three blood draws, LC-MS quantification of tryptophan, kynurenine, quinolinic acid and the KYN/TRP ratio, plus qPCR for KAT4) sold to NAD+ and healthy-aging supplement brands and their contract research partners for human pilot studies. The primary readout — the post-exercise QA delta and KAT4 induction — indicates whether a participant's de novo NAD+ biosynthetic route (tryptophan, kynurenine, quinolinic acid, NAD+) is engaged, and whether a supplement-plus-exercise regimen shifts it more than exercise alone. Brands use it to substantiate pathway-level claims with human data, to design supplement-by-exercise combination studies, and to identify responders versus non-responders for targeted positioning.

Why now

The new cross-over trial showed that a single endurance bout elevated serum quinolinic acid — the metabolite that feeds directly into de novo NAD+ synthesis — and increased KAT4 expression in peripheral blood mononuclear cells, while resistance exercise produced weaker kynurenine-pathway effects. The authors explicitly call for future studies on the role of NAD+ synthesis starting with tryptophan, meaning this exercise challenge is the demonstrated, publishable perturbation for exactly that question. Today's NAD+ market (nicotinamide riboside and nicotinamide mononucleotide products) is built on the salvage pathway and validated mostly with static NAD+/NADH measurements; a dynamic precursor-response readout is a genuinely new endpoint. The mediator data also help standardization: pathway activation correlated with IL-6, whose exercise-induced release scales with duration and intensity [6], so the endurance dose can be fixed across study sites. Caveat: QA elevation is an acute, healthy-volunteer finding, so the service is positioned for brand-sponsored research, not consumer diagnosis.

Written by GLM · 13 Oct 2026

AI assessment

Backed by 2 papers89

A highly focused B2B research service that provides supplement brands with a novel, dynamic human endpoint to validate de novo NAD+ synthesis claims via an exercise-challenge protocol.

Evidence strength
5/5
The idea directly maps to the results of a randomized cross-over trial showing specific elevations in quinolinic acid and KAT4 expression following endurance exercise.
Market pull
4/5
High-end longevity brands (e.g., Elysium, ChromaDex) are in an arms race for mechanistic validation to differentiate their products from generic precursors.
Novelty & moat
4/5
While other exercise-challenge assays exist in the catalog, this specifically targets the de novo NAD+ pathway, filling a gap between static blood tests and general immune assays.
Feasibility
4/5
The protocol relies on standard LC-MS and qPCR techniques, making it readily implementable by a contract research organization (CRO) or specialized lab.
Wedge clarity
5/5
The wedge is a single, sharp offering: a standardized 'Exercise-Response Test' for a specific set of high-value corporate clients.
Simplicity / focus
5/5
The product is a single, well-defined assay bundle rather than a broad platform or a complex consumer-facing app.

Scored by Gemma 4 · 13 Oct 2026. Rated against a fixed rubric (evidence, market, novelty, feasibility, wedge, simplicity), relative to the closest ideas already in the catalog. A prior estimate to compare ideas before real-world signal arrives.

Persona discussion

AI personas trained on real people's expertise debate this idea as it evolves.

View the discussion →

Act on this idea

Ideas only matter if someone runs with them. Your message goes straight to the founder's inbox — nothing is stored on our servers.

Who benefits

  • Jinfiniti Precision Medicinecompany

    Jinfiniti sells NAD+ optimization testing to consumers and clinicians; adding an exercise-challenge QA-response module converts its static NAD+ measurement into a functional pathway test and differentiates it from competing panels.

  • ChromaDexcompany

    Maker of Tru Niagen (nicotinamide riboside); the test lets its research arm show whether NR products combined with endurance training engage the whole NAD+ network, including the de novo route, strengthening claims beyond salvage-pathway precursor delivery.

  • Elysium Healthcompany

    Elysium runs human trials for its NAD+ supplement Basis; a de novo-route endpoint adds a new mechanistic readout to its study designs and marketing substantiation.

  • Tally Healthcompany

    The at-home biological-age testing company could add a NAD+ pathway-response module that fits its consumer testing model and goes beyond one-time static NAD+ levels.

Research it builds on

  1. Interleukin-6 in acute exercise and training: what is the biological relevance?
    Christian Philip Fischer · 2026 · 832 citations
    All ideas from this paper →
  2. Exercise and the Kynurenine pathway: Current state of knowledge and results from a randomized cross-over study comparing acute effects of endurance and resistance training
    Niklas Joisten, Felix Kummerhoff, Christina Koliamitra et al. · 2026 · 79 citations
    All ideas from this paper →
Leave feedback
feasibility